Ingalls & Snyder’s Heron Therapeutics HRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding HRTX
Ingalls & Snyder's HRTX Position: Q3 2026 in Review
Ingalls & Snyder sold out of Heron Therapeutics (HRTX) in Q3 2026, closing a stake of 11,415 shares — an estimated $5K sold.
Ingalls & Snyder first reported a position in HRTX in Q2 2022 and held it in 17 quarters. The position peaked at $60K in Q3 2022. 159 funds tracked by Wall St. Rank hold HRTX as of Q3 2026.
- Ingalls & Snyder reported no remaining Heron Therapeutics position as of Q3 2026 after selling out during the quarter.
- Ingalls & Snyder sold 11,415 Heron Therapeutics shares in Q3 2026, an estimated $5K.
- Ingalls & Snyder first reported a position in Heron Therapeutics in Q2 2022 and held it in 17 quarters.
- Ingalls & Snyder's Heron Therapeutics position peaked at $60K in Q3 2022.
- 159 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2026.
Based on Ingalls & Snyder's 13F filing for Q3 2026, filed 12 Nov 2026.